Mutations in the B30.2 and the central helical scaffold domains of pyrin differentially affect inflammasome activation.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
25 03 2023
Historique:
received: 08 11 2022
accepted: 15 03 2023
revised: 11 03 2023
medline: 28 3 2023
entrez: 25 3 2023
pubmed: 26 3 2023
Statut: epublish

Résumé

Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disorder. FMF is caused by mutations in the MEFV gene, encoding pyrin, an inflammasome sensor. The best characterized pathogenic mutations associated with FMF cluster in exon 10. Yet, mutations have been described along the whole MEFV coding sequence. Exon 10 encodes the B30.2 domain of the pyrin protein, but the function of this human-specific domain remains unclear. Pyrin is an inflammasome sensor detecting RhoA GTPase inhibition following exposure to bacterial toxins such as TcdA. Here, we demonstrate that the B30.2 domain is dispensable for pyrin inflammasome activation in response to this toxin. Deletion of the B30.2 domain mimics the most typical FMF-associated mutation and confers spontaneous inflammasome activation in response to pyrin dephosphorylation. Our results indicate that the B30.2 domain is a negative regulator of the pyrin inflammasome that acts independently from and downstream of pyrin dephosphorylation. In addition, we identify the central helical scaffold (CHS) domain of pyrin, which lies immediately upstream of the B30.2 domain as a second regulatory domain. Mutations affecting the CHS domain mimic pathogenic mutations in the B30.2 domain and render the pyrin inflammasome activation under the sole control of the dephosphorylation. In addition, specific mutations in the CHS domain strongly increase the cell susceptibility to steroid catabolites, recently described to activate pyrin, in both a cell line model and in monocytes from genotype-selected FMF patients. Taken together, our work reveals the existence of two distinct regulatory regions at the C-terminus of the pyrin protein, that act in a distinct manner to regulate positively or negatively inflammasome activation. Furthermore, our results indicate that different mutations in pyrin regulatory domains have different functional impacts on the pyrin inflammasome which could contribute to the diversity of pyrin-associated autoinflammatory diseases.

Identifiants

pubmed: 36966139
doi: 10.1038/s41419-023-05745-9
pii: 10.1038/s41419-023-05745-9
pmc: PMC10039897
doi:

Substances chimiques

Inflammasomes 0
MEFV protein, human 0
Pyrin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

213

Informations de copyright

© 2023. The Author(s).

Références

J Genet Eng Biotechnol. 2022 Feb 21;20(1):31
pubmed: 35190906
Ann Rheum Dis. 2012 Dec;71(12):1961-5
pubmed: 22580583
Nat Genet. 1997 Sep;17(1):25-31
pubmed: 9288094
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14384-14389
pubmed: 27911804
Cell Rep. 2022 Oct 11;41(2):111472
pubmed: 36223753
Ann Rheum Dis. 2021 Jan;80(1):128-132
pubmed: 33037005
Mol Cell. 2013 Jan 24;49(2):331-8
pubmed: 23246432
Nat Immunol. 2020 Aug;21(8):857-867
pubmed: 32601469
Mol Cell. 2002 Aug;10(2):417-26
pubmed: 12191486
Nature. 2014 Sep 11;513(7517):237-41
pubmed: 24919149
Rheumatology (Oxford). 2020 Mar 1;59(3):554-558
pubmed: 31384939
Pathog Dis. 2018 Apr 1;76(3):
pubmed: 29718184
EMBO Mol Med. 2019 Nov 7;11(11):e10547
pubmed: 31589380
J Clin Immunol. 2021 Aug;41(6):1187-1197
pubmed: 33733382
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70
pubmed: 21307310
Nat Immunol. 2016 Aug;17(8):914-21
pubmed: 27270401
Infect Immun. 1987 Jan;55(1):35-43
pubmed: 3793234
Sci Transl Med. 2016 Mar 30;8(332):332ra45
pubmed: 27030597
Immunol Rev. 2011 Sep;243(1):174-90
pubmed: 21884176
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7
pubmed: 16785446
Sci Rep. 2015 Jun 04;5:10819
pubmed: 26043233
Nat Immunol. 2017 Jul 19;18(8):832-842
pubmed: 28722725
Ann Rheum Dis. 2014 Feb;73(2):462-9
pubmed: 23505242
Nat Commun. 2018 Jan 16;9(1):242
pubmed: 29339744
J Pediatr. 2019 Jun;209:12-16.e1
pubmed: 30928144
Arthritis Rheum. 2005 Jun;52(6):1848-57
pubmed: 15934090
J Allergy Clin Immunol. 2019 Nov;144(5):1438-1441.e12
pubmed: 31542286
Rheumatology (Oxford). 2018 Jan 1;57(1):100-111
pubmed: 29040788
Proteins. 2018 Jun;86(6):676-683
pubmed: 29575132
J Cell Biol. 2015 Sep 14;210(6):973-89
pubmed: 26347139
Microb Pathog. 1987 May;2(5):307-18
pubmed: 2467163
J Exp Med. 2017 Jun 5;214(6):1725-1736
pubmed: 28465465
Am J Med Genet A. 2004 Jan 1;124A(1):67-73
pubmed: 14679589
Ann Rheum Dis. 2017 Dec;76(12):2085-2094
pubmed: 28835462
Hum Mutat. 2008 Jun;29(6):803-8
pubmed: 18409191
J Immunol. 2009 Jul 15;183(2):787-91
pubmed: 19570822
Cell Death Differ. 2007 Aug;14(8):1457-66
pubmed: 17431422
Eur J Hum Genet. 2001 Jul;9(7):473-83
pubmed: 11464238
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4857-66
pubmed: 27482109
Hum Mol Genet. 1998 Aug;7(8):1317-25
pubmed: 9668175
J Biol Chem. 2019 Mar 8;294(10):3359-3366
pubmed: 30647128
J Mol Biol. 2009 Nov 27;394(2):226-36
pubmed: 19729025
Cell. 1997 Aug 22;90(4):797-807
pubmed: 9288758

Auteurs

Daria Chirita (D)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.

Pauline Bronnec (P)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.

Flora Magnotti (F)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.

Sarah Dalmon (S)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.

Amandine Martin (A)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.

Michel Popoff (M)

Bacterial Toxins, Institut Pasteur, Paris, France.

Mathieu Gerfaud-Valentin (M)

Department of Internal Medicine, University Hospital Croix-Rousse, Lyon 1 University, Lyon, France.

Pascal Sève (P)

Department of Internal Medicine, University Hospital Croix-Rousse, Lyon 1 University, Lyon, France.

Alexandre Belot (A)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.
LIFE, Lyon Immunopathology FEderation, Lyon, France.
Department of Pediatric Nephrology, Rheumatology, Dermatology, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Hôpital Femme Mère Enfant, CHU Lyon, Bron, France.

Anne Contis (A)

Department of Internal Medicine, Saint André Hospital, CHU Bordeaux, Bordeaux, France.

Agnes Duquesne (A)

Department of Pediatric Nephrology, Rheumatology, Dermatology, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Hôpital Femme Mère Enfant, CHU Lyon, Bron, France.

Gaetane Nocturne (G)

Department of Rheumatology, Université Paris-Saclay, INSERM UMR1184: Center for immunology of viral infections and autoimmune diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin Bicêtre, France.

Irene Lemelle (I)

Paediatric onco-haematology, University Hospital of Nancy - Children's hospital, Vandoeuvre-Lès-Nancy, France.

Sophie Georgin-Lavialle (S)

Sorbonne University, department of internal medicine, Tenon hospital, DMU 3ID, AP-HP, National reference center for autoinflammatory diseases and inflammatory Amyloidosis (CeRéMAIA), INSERM U938, Paris, France.

Guilaine Boursier (G)

Department of Molecular genetics and Cytogenomics, CHU Montpellier, Univ Montpellier, Reference Center for Autoinflammatory Diseases and Amyloidosis (CeRéMAIA), Montpellier, France.

Isabelle Touitou (I)

Department of Molecular genetics and Cytogenomics, CHU Montpellier, Univ Montpellier, Reference Center for Autoinflammatory Diseases and Amyloidosis (CeRéMAIA), Montpellier, France.

Yvan Jamilloux (Y)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France.
Department of Internal Medicine, University Hospital Croix-Rousse, Lyon 1 University, Lyon, France.
LIFE, Lyon Immunopathology FEderation, Lyon, France.

Thomas Henry (T)

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, LYON, France. thomas.henry@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH